Seladelpar in primary biliary cholangitis

被引：0
|
作者：
Kotsiliti, Eleni
机构：
[1] Nature Reviews Gastroenterology & Hepatology,
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2024年 / 21卷 / 05期
关键词：
D O I：
10.1038/s41575-024-00922-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：300 / 300
页数：1
相关论文
共 50 条
  • [41] A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
    Bowlus, Christopher L.
    Galambos, Michael R.
    Aspinall, Richard J.
    Hirschfield, Gideon M.
    Jones, David E. J.
    Doerffel, Yvonne
    Gordon, Stuart C.
    Harrison, Stephen A.
    Kremer, Andreas E.
    Mayo, Marlyn J.
    Thuluvath, Paul J.
    Levy, Cynthia
    Swain, Mark G.
    Neff, Guy W.
    Sheridan, David A.
    Stanca, Carmen M.
    Berg, Christoph P.
    Goel, Aparna
    Shiffman, Mitchell L.
    Vierling, John M.
    Boudes, Pol
    Steinberg, Alexandra
    Choi, Yun-Jung
    McWherter, Charles A.
    JOURNAL OF HEPATOLOGY, 2022, 77 (02) : 353 - 364
  • [42] LONG-TERM SAFETY OF SELADELPAR 10 MG WITH UP TO 5 YEARS OF TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
    Trivedi, Palak
    Gordon, Stuart
    Gulamhusein, Aliya
    Villamil, Alejandra
    Lawitz, Eric
    Vierling, John
    Londono, Maria Carlota
    Kremer, Andreas
    Bowlus, Christopher
    Proehl, Sarah
    Zhuo, Shuqiong
    Crittenden, Daria
    McWherter, Charles
    HEPATOLOGY, 2024, 80 : S1823 - S1824
  • [43] Seladelpar's mechanism of action as a potential treatment for primary biliary cholangitis and non-alcoholic steato-hepatitis
    Boudes, P.
    Choi, Y. -J.
    Steinberg, A.
    Bergheanu, S.
    Mcwherter, C.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S235 - S236
  • [44] SELADELPAR IMPROVED THE LIPID PROFILE OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): RESULTS FROM PHASE 2 AND 3 CLINICAL STUDIES
    Bowlus, Christopher L.
    Choi, Yun-Jung
    Yang, Ke
    Crittenden, Barry
    Kim, Dennis
    McWherter, Charles
    HEPATOLOGY, 2022, 76 : S1508 - S1508
  • [45] Planned Seladelpar Phase 3 Study in Primary Biliary Cholangitis. a Tipping Point Analysis to Determine Failure Boundaries.
    Amato, Gianni
    Hansen, Bettina E.
    Hirschfield, Gideon
    Boudes, Pol
    Rosen, Allan
    HEPATOLOGY, 2018, 68 : 1110A - 1111A
  • [46] Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
    Ahn, Dong-Won
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 75 (05): : 246 - 256
  • [47] Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape
    Bhushan, Sheena
    Sohal, Aalam
    Kowdley, Kris V.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2025, 120 (01): : 151 - 158
  • [48] EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED CIRRHOSIS IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL
    Villamil, Alejandra
    Younes, Ziad
    Bowlus, Christopher
    Vierling, John
    Vasura, Adam
    Galli, Andrea
    Rabinovitz, Mordechai
    Nevens, Frederik
    Carroll, Susheela
    Yang, Ke
    Crittenden, Daria
    McWherter, Charles
    Lawitz, Eric
    HEPATOLOGY, 2024, 80 : S517 - S518
  • [49] Improvement in Predicted Survival after 26 Weeks of Treatment with Seladelpar in Patients with Primary Biliary Cholangitis and an Incomplete Response to Ursodeoxycholic Acid
    Hansen, Bettina E.
    Gulamhusein, Aliya
    Amato, Gianni
    Boudes, Po
    Hirschfield, Gideon
    HEPATOLOGY, 2018, 68 : 1087A - 1088A
  • [50] Elafibranor in primary biliary cholangitis
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2024, 21 : 2 - 2
12345